Recent Financings of Private Companies (09/11)
This article was originally published in Start Up
Executive Summary
Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.
You may also be interested in...
Y-mAbs Gives Thanks For First Approved Drug Danyelza
US regulators refused to accept the file for one of Y-mAbs's neuroblasoma drugs – omburtamab – in October but have given the green light to a second one, naxitamab.
Sandoz Aims For $6bn Biosimilar Business By 2030
Fueled by a pipeline of more than 15 biosimilar candidates, Sandoz is aiming to treble the size of its $2bn global biosimilars business by 2030, targeting the US, Europe and Japan. Management spoke at length about the firm’s achievements and prospects during a meeting of parent Novartis’ management.
Biogen Bets Big To Bag Sage Depression And Tremor Drugs
Rather than hitting the acquisition trial, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.
Need a specific report? 1000+ reports available
Buy Reports